Is Mabion S.A. (MAB.WA) a Buy, Sell, or Hold?
WSE : MAB.WA
Mabion S.A.
$7.49 PLN
$0.03 (0.4%)
- Volume
- 5.57K
- Average Volume
- 26.52K
- Market Capitalization
- $121.06M
- P/E Ratio
- -2.12
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $10.00
- Year Low
- $6.70
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.31
Company Overview
WSE
Krzysztof Kaczmarczyk
Biotechnology
Healthcare
MAB.WA
206
PL
PLN
Liquidity Metrics
0.65
0.31
0.27
0.14
0.00
Sales & Valuation
$15.76M
6.87
3.10
-3.03
-2.47
Profitability
-$3.87
-$62.61M
-324.20%
-324.20%
-95.68%
-51.98%
P/E Metrics
-2.12
0.03
0.03
Analyst Price Target & Rating
1/5
0 Analysts
%
Financial Health Scores
-3.44
3/9
-$31.96M
$109.85M
$70.76M
-$47.55M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Paulina Tobola | Head of Analytics Development Department |
| Krzysztof Kaczmarczyk | Chief Executive Officer & President of Management Board |
| Julita Balcerek | Member of the Management Board, Operations Director & Chief Operating Officer |
| Adam Pietruszkiewicz | Chief Commercial Officer, Business Development Director & Member of Management Board |
| Joanna Krolasik | Head of Microbiology Division |
| Pawel Pobiedzinski | Head of Logistics & Procurement |
Poll Results
No votes yet today — be the first to share your view!
About Mabion S.A. (WSE:MAB.WA) Stock
Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the manufacturing and commercialization of therapies designed to combat a wide range of diseases, including neoplastic (cancer), autoimmune, metabolic, and neurological disorders. Key products in its portfolio include MabionCD20 and MabionHER2. Established in 2007, Mabion S.A. maintains its headquarters in Konstantynów Lódzki, Poland. ...
Frequently Asked Questions
-
What is the current Mabion S.A. (MAB.WA) stock price?
-
Mabion S.A.(WSE:MAB.WA) stock price is $7.49 in the last trading session. During the trading session, MAB.WA stock reached the peak price of $10 while $6.7 was the lowest point it dropped to. The percentage change in MAB.WA stock occurred in the recent session was 0.4% while the dollar amount for the price change in MAB.WA stock was $0.03.
-
MAB.WA's industry and sector of operation?
-
The WSE listed MAB.WA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MAB.WA?
-
Paulina Tobola | Head of Analytics Development Department
Krzysztof Kaczmarczyk | Chief Executive Officer & President of Management Board
Julita Balcerek | Member of the Management Board, Operations Director & Chief Operating Officer
Adam Pietruszkiewicz | Chief Commercial Officer, Business Development Director & Member of Management Board
Joanna Krolasik | Head of Microbiology Division -
How many employees does MAB.WA have?
-
Number of MAB.WA employees currently stands at 206. MAB.WA operates from Medical Biotechnology Scientific and Industrial Complex, Konstantynów Lódzki, LDZ 95-050, PL.
-
Link for MAB.WA official website?
-
Official Website of MAB.WA is: https://www.mabion.eu
-
How do I contact MAB.WA?
-
MAB.WA could be contacted at phone #48 42 207 7890 and can also be accessed through its website. MAB.WA operates from Medical Biotechnology Scientific and Industrial Complex, Konstantynów Lódzki, LDZ 95-050, PL.
-
How many shares of MAB.WA are traded daily?
-
The average number of MAB.WA shares traded daily for last 3 months was 26.52K.
-
What is the market cap of MAB.WA currently?
-
The market value of MAB.WA currently stands at $121.06M with its latest stock price at $7.49